Intuitive Surgical (NASDAQ:ISRG) Given New $400.00 Price Target at Mizuho

Posted by Francis Steltz on Oct 21st, 2026

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) had its price target dropped by research analysts at Mizuho from $415.00 to $400.00 in a research note issued to investors on Wednesday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical equipment provider’s stock. Mizuho’s target price would indicate a potential downside of 8.68% from the stock’s current price.

ISRG has been the topic of several other reports. Royal Bank Of Canada reduced their price objective on Intuitive Surgical from $650.00 to $600.00 and set an “outperform” rating on the stock in a research report on Monday, July 13th. Robert W. Baird lifted their price objective on Intuitive Surgical from $513.00 to $550.00 and gave the stock an “outperform” rating in a research report on Wednesday. Raymond James Financial reiterated an “outperform” rating and set a $480.00 price objective on shares of Intuitive Surgical in a research report on Wednesday. Wells Fargo & Company reissued an “overweight” rating on shares of Intuitive Surgical in a research note on Wednesday. Finally, Weiss Ratings restated a “hold (c)” rating on shares of Intuitive Surgical in a report on Friday, August 14th. Twenty-five research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Intuitive Surgical currently has an average rating of “Moderate Buy” and an average target price of $500.57.

Read Our Latest Stock Analysis on Intuitive Surgical

Intuitive Surgical Price Performance

Shares of NASDAQ ISRG opened at $438.00 on Wednesday. Intuitive Surgical has a 12-month low of $328.57 and a 12-month high of $603.88. The company has a market capitalization of $154.74 billion, a PE ratio of 50.17, a price-to-earnings-growth ratio of 3.27 and a beta of 1.46. The firm’s 50-day moving average is $392.96 and its two-hundred day moving average is $409.06.

Intuitive Surgical (NASDAQ:ISRG – Get Free Report) last issued its quarterly earnings data on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.65 by $0.35. The firm had revenue of $3.05 billion during the quarter, compared to the consensus estimate of $2.91 billion. Intuitive Surgical had a return on equity of 16.91% and a net margin of 28.45%. The company’s quarterly revenue was up 21.7% compared to the same quarter last year. During the same period in the previous year, the firm posted $2.40 EPS. On average, analysts forecast that Intuitive Surgical will post 8.87 EPS for the current fiscal year.

Insider Buying and Selling

In other Intuitive Surgical news, Director Amy Ladd sold 400 shares of the business’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $379.00, for a total value of $151,600.00. Following the completion of the transaction, the director directly owned 251 shares in the company, valued at approximately $95,129. The trade was a 61.44% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, VP Fredrik Widman sold 1,089 shares of the stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $374.44, for a total value of $407,765.16. Following the transaction, the vice president directly owned 1,026 shares in the company, valued at approximately $384,175.44. This represents a 51.49% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 12,370 shares of company stock worth $4,891,989 in the last three months. 0.60% of the stock is currently owned by insiders.

Institutional Trading of Intuitive Surgical

A number of institutional investors have recently made changes to their positions in the stock. 3Chopt Investment Partners LLC lifted its position in Intuitive Surgical by 5.2% in the first quarter. 3Chopt Investment Partners LLC now owns 462 shares of the medical equipment provider’s stock worth $213,000 after purchasing an additional 23 shares during the period. Vermillion Wealth Management Inc. boosted its stake in Intuitive Surgical by 58.1% during the 1st quarter. Vermillion Wealth Management Inc. now owns 68 shares of the medical equipment provider’s stock valued at $31,000 after purchasing an additional 25 shares in the last quarter. W.G. Shaheen & Associates DBA Whitney & Co boosted its stake in Intuitive Surgical by 1.0% during the 1st quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 2,542 shares of the medical equipment provider’s stock valued at $1,172,000 after purchasing an additional 25 shares in the last quarter. Blue Fin Capital Inc. increased its position in shares of Intuitive Surgical by 0.5% during the 1st quarter. Blue Fin Capital Inc. now owns 4,794 shares of the medical equipment provider’s stock valued at $2,210,000 after purchasing an additional 25 shares during the period. Finally, Red Spruce Capital LLC increased its position in shares of Intuitive Surgical by 4.1% during the 2nd quarter. Red Spruce Capital LLC now owns 640 shares of the medical equipment provider’s stock valued at $255,000 after purchasing an additional 25 shares during the period. 83.64% of the stock is owned by institutional investors and hedge funds.

Intuitive Surgical News Summary

Here are the key news stories impacting Intuitive Surgical this week:

Positive Sentiment: Q3 results exceeded expectations: Revenue rose 21.7% year over year to $3.05 billion, above the approximately $2.91 billion consensus, while adjusted earnings reached $3.00 per share versus estimates of roughly $2.61–$2.65. Intuitive Surgical Q3 Earnings and Revenues Top Estimates
Positive Sentiment: Underlying demand remained healthy: Worldwide procedures increased approximately 15%, including 14% growth for da Vinci procedures and 31% for Ion procedures. Intuitive placed 546 robotic systems, up from 427 a year earlier. Intuitive Announces Third Quarter Earnings
Positive Sentiment: Potentially broader adoption: Intuitive plans to extend instrument life and reduce per-procedure costs in 2027. Although this could pressure near-term revenue per procedure, management views it as a way to make robotic surgery more affordable and expand the installed base. Why ISRG Is Lowering Instrument Costs Despite Strong Profitability
Neutral Sentiment: Leasing is supporting placements: Operating leases represented 54% of second-quarter da Vinci placements, up from 49% a year earlier. Leasing may accelerate hospital adoption, but it can also make Intuitive’s returns more dependent on future procedure volume. Does Leasing Make Growth More Durable or More Capital Intensive?
Negative Sentiment: Large antitrust settlement charge hurt GAAP earnings: Intuitive recorded a $450 million pre-tax charge, or $347 million after tax, related to a proposed settlement. GAAP net income fell to $523 million, or $1.49 per share, from $704 million, or $1.95 per share, a year earlier; court approval is still required. Antitrust Settlement Charge Overshadows Strong Q3 Growth
Negative Sentiment: 2026 procedure-growth guidance was narrowed to 14%–15%: The tighter outlook, along with planned pricing actions targeting a 3%–5% reduction in instrument and accessory costs per procedure, raised concerns that growth and margins may moderate. Intuitive Narrows 2026 Procedure Growth Outlook

About Intuitive Surgical

(Get Free Report)

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company’s primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.